Reading BMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMY free→Reading BMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMY free→QuarterlyIQ Insights · BMY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On April 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the first quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On February 5, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the fourth quarter of 2025 and full year of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Other Events. Indenture On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company (the “Issuer”), a designated activity company incorporated under the laws of Ireland and a wholly-owned subsidiary of Bristol-Myers Squibb Company (the “Company”), completed the public offering (the “Offering”) of (i) €750,000,000 aggregate principal amount of 2.973% Notes due 2030 (the “2030 Notes”), (ii) €1,150,000,000 aggregate principal amount of 3.363% Notes due 2033 (the “2033 Notes”),…
Results of Operations and Financial Condition. On October 30, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the third quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 31, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On July 25, 2025, Bristol-Myers Squibb Company (the “Company”) announced that Dr. Samit Hirawat, Chief Medical Officer and Head of Development, will leave the Company by November 1, 2025. In connection with his departure, Dr. Hirawat will transition from his current role as Executive Vice President, Chief Medical Officer and Head of Development,…
Results of Operations and Financial Condition. On April 24, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025. Ms. Leung is expected to remain with the Company for a transition period until her successor’s appointment in order to assist with the transition of her dutie…
Results of Operations and Financial Condition. On February 6, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2024 and full year of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On October 31, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 26, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024. The size of the Board was increased to eleven, effective July 1, 2024, in connection with the election of Mr. McMullen. Mr. McMullen is 63 years old and…
Results of Operations and Financial Condition. On April 25, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) On March 13, 2024, Mr. Gerald Storch notified the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) that he will not stand for re-election to the Board of the Company at the 2024 Annual Meeting of Shareholders. The Board also set the number of directors at ten, effective immediately after the 2024 Annual Meeting of…
Other Events. On March 18, 2024, Bristol-Myers Squibb Company (“BMS”) issued a press release announcing the completion of its previously announced acquisition (the “Acquisition”) of Karuna Therapeutics, Inc. (“Karuna”). In the Acquisition, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the Acquisition (other than certain excluded shares as described in the agreement and plan of merger entered into among BMS, Karuna and Miramar Merger Sub In…
does not purport to be complete and is qualified in its entirety by reference to the full text of the Base Indenture, the Fifteenth Supplemental Indenture and the Notes. The Base Indenture was filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K dated May 27, 1993 and filed on June 3, 1993 and the terms of which are incorporated herein by reference. The Fifteenth Supplemental Indenture is filed as Exhibit 4.1 to this Current Report on Form 8-K and its terms are incorporated herein…
Other Events. Indenture On February 22, 2024, Bristol-Myers Squibb Company (the “Company”) completed the public offering (the “Offering”) of (i) $500,000,000 aggregate principal amount of Floating Rate Notes due 2026 (the “Floating Rate Notes”), (ii) $1,000,000,000 aggregate principal amount of 4.950% Notes due 2026 (the “2026 Notes”) (iii) $1,000,000,000 aggregate principal amount of 4.900% Notes due 2027 (the “2027 Notes”), (iv) $1,750,000,000 aggregate principal amount of 4.900% Notes due…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”). Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024. Mr. Holzer, 48, joined the Company in 2001. Most recently, from 2021 to…
Results of Operations and Financial Condition. On February 2, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2023 and full year of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Other Events. On December 22, 2023, Bristol-Myers Squibb Company (“BMS”), and Karuna Therapeutics, Inc. (“Karuna”), issued a joint press release announcing that BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS (“Merger Sub”), have signed an agreement and plan of merger (the “Merger Agreement”) providing that, on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into Karuna, with Karuna surviving as a wholly owned subsidiary of B…
Other Events. Indenture On November 13, 2023, Bristol-Myers Squibb Company (the “Company”) completed the public offering (the “Offering”) of (i) $1,000,000,000 aggregate principal amount of 5.750% Notes due 2031, (ii) $1,000,000,000 aggregate principal amount of 5.900% Notes due 2033, (iii) $1,250,000,000 aggregate principal amount of 6.250% Notes due 2053, and (iv) $1,250,000,000 aggregate principal amount of 6.400% Notes due 2063 (collectively, the “Notes”). The Company intends to use the n…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b)(c) On April 26, 2023, Bristol Myers Squibb Company (the “Company”) filed a Form 8-K to announce the retirement of Giovanni Caforio, M.D. as Chief Executive Officer and his election as Executive Chairman of the Board of Directors of the Company (the “Board”), effective November 1, 2023, and the appointment of Christopher Boerner, Ph.D. as Chief E…
Results of Operations and Financial Condition. On October 26, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Other Events. On August 9, 2023, Bristol-Myers Squibb Company (“BMS”) entered into accelerated share repurchase (“ASR”) transactions under agreements with each of Bank of America, N.A., Citibank, N.A., JPMorgan Chase Bank, National Association and Morgan Stanley & Co. LLC (each, an “ASR Agreement” and collectively, the “ASR Agreements”), to repurchase an aggregate of $4.0 billion (the “Repurchase Price”) of BMS common stock, par value $0.10 per share (the “Common Stock”). The ASR transactions…
Results of Operations and Financial Condition. On July 27, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Importance-ranked changes since the prior daily snapshot.
Confidence changed from 'high' to 'medium'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.